Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics save search
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
NUVB | $2.685 0.19% 400K
|
|
| O: -4.64%
H: 1.3%
C: -0.97%
acquisition therapeutics
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Published: 2024-04-10 (Crawled : 16:00) - globenewswire.com
APRE | $5.1201 870
|
Health Technology
|
| O: -2.14%
H: 4.91%
C: 4.91%
apr-1051 meeting therapeutics
Understanding the mRNA Therapeutics Market's -8.6% Decline: Insights from BCC Research
Published: 2024-04-10 (Crawled : 14:30) - prnewswire.com
OMGA | $2.365 -1.05% 130K
|
|
| O: -0.33%
H: 0.17%
C: 0.0%
CVAC | $2.54 0.4% 350K
|
Health Technology
|
| O: -0.67%
H: 1.36%
C: 0.0%
BNTX | News | $88.24 0.26% 180K
|
Health Technology
|
| O: -1.69%
H: 0.97%
C: 0.14%
mrna research therapeutics
Aptevo Therapeutics Provides Pipeline Update
Published: 2024-04-10 (Crawled : 14:00) - biospace.com/
APVO | $0.737 3.8% 230K
|
Health Technology
|
| O: -6.44%
H: 1.64%
C: -21.31%
update pipeline therapeutics
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
CYTO | $1.38 -1.43% 43K
|
Manufacturing
|
| O: -5.56%
H: 7.49%
C: 6.95%
business year therapeutics financial results
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
CMPX | $1.53 2.69% 6.1K
|
Professional, Scientific, and T...
|
| O: -8.93%
H: 12.03%
C: 1.27%
therapeutics
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
Published: 2024-04-10 (Crawled : 12:00) - biospace.com/
ATHE | $2.13 10K
|
Health Technology
|
| O: 1.05%
H: 22.28%
C: 13.47%
ath434 drug congress world therapeutics usa
Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistance Mechanisms to ACR-368
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
ACRV | $9.95 4.63% 130K
|
|
| O: -2.7%
H: 11.97%
C: 11.0%
acr-2316 precision acr-368 for meeting therapeutics
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
ZVRA | $4.57 31K
|
n/a
|
| O: -0.42%
H: 6.74%
C: 3.58%
therapeutics
Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
UNCY | $1.15 130K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.0%
C: -1.52%
conference therapeutics growth
BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
BTAI | News | $3.005 5.44% 240K
|
Health Technology
|
| O: 0.96%
H: 1.9%
C: 0.0%
bxcl501 alzheimer’s dementia for trial therapeutics
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
AXSM | $74.175 4.32% 300K
|
Health Technology
|
| O: -2.66%
H: 1.26%
C: 0.37%
first report therapeutics financial results
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Published: 2024-04-10 (Crawled : 11:00) - globenewswire.com
SNYNF | News | $92.7 600K
|
Health Technology
|
| O: -0.01%
H: 0.0%
C: 0.0%
SNY | News | $47.85 1.49% 920K
|
Health Technology
|
| O: -0.32%
H: 0.0%
C: 0.0%
NRIX 6 d | $14.19 4.49% 230K
|
Health Technology
|
| O: 18.35%
H: 1.98%
C: -5.88%
first update therapeutics financial results
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
Published: 2024-04-10 (Crawled : 10:00) - prnewswire.com
BCLI A | $0.531 -1.69% 110K
|
Health Technology
|
| O: -20.14%
H: 0.0%
C: 0.0%
als biomarker publication cell trial therapeutics
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
Published: 2024-04-09 (Crawled : 23:00) - alteritytherapeutics.com
ATHE | $2.13 10K
|
Health Technology
|
| O: 1.05%
H: 22.28%
C: 13.47%
ath434 drug congress world therapeutics usa
Corneal Edema Therapeutics Market to Grow Significantly at a CAGR of 8.54% in the US by 2034 | DelveInsight
Published: 2024-04-09 (Crawled : 22:00) - prnewswire.com
KOD | News | $3.445 0.73% 180K
|
Health Technology
|
| O: -4.47%
H: 5.97%
C: 4.92%
therapeutics market
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Published: 2024-04-09 (Crawled : 21:00) - globenewswire.com
FHTX | $5.33 5.55% 16K
|
Health Technology
|
| O: -4.01%
H: 9.92%
C: 1.11%
fhd-909 ep300 preclinical therapeutics potential
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
LLY | News | $741.37 1.37% 800K
|
Health Technology
|
| O: -0.71%
H: 0.0%
C: 0.0%
ORIC | $8.905 2.12% 80K
|
Health Technology
|
| O: -2.81%
H: 1.54%
C: -3.57%
NRIX 6 d | $14.19 4.49% 230K
|
Health Technology
|
| O: 18.35%
H: 1.98%
C: -5.88%
therapeutics
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Published: 2024-04-09 (Crawled : 17:00) - globenewswire.com
NRIX 6 d | $14.19 4.49% 230K
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
nx-5948 first cell for therapeutics
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
CMPX | $1.53 2.69% 6.1K
|
Professional, Scientific, and T...
|
| O: 2.06%
H: 0.0%
C: 0.0%
association tumors cancer research for meeting therapeutics negative
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
OPRT | News | $3.37 49.78% 8.9M
|
Finance
MTC | $2.14 37.18% 4.9M
|
Technology Services
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.79 27.86% 2.6M
|
n/a
PALI | $6.29 27.59% 22M
|
Manufacturing
MCRB | $0.7902 26.51% 6.9M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.